ArticleFrontiers in pharmacology2025
Antiproliferative effects of
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics analysis reveals psoralen to suppresses renal cell carcinoma through the PI3K/AKT pathway.Molecular and clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: One of the most well-known and deadly types of cancer is renal cell carcinoma (RCC). Not much research has been done on Methods: UPLC-Q-TOF-MS/MS was used to systematically identify the components of TX. ACHN cell lines were used to assess TX's pharmacological studies. Next, complexes with compound and gene will be included based on molecular docking and molecular dynamics simulations. In the end, signaling pathway analysis were used to elucidate the intricate mechanisms. Results: Analysis using UPLC-Q-TOF-MS/MS identified 47 major compounds in TX. Conclusion: This study utilized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.